Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-143

it is comical to think one persons posts on hotcopper (the rag mag of the Stockmarket) has any influence over share price trends. I’ll give Giddy (aka Karen) credit where credit is due he has nailed the hopeless CRs and Biotron inept tardiness in this department time and time again. MM has totally proven she is beyond hopeless at managing timelines, communicating to shareholders and aligning shareholder interests with credit raising timing. We can only hope the science will speak for itself as shareholders are up against the odds with such a hopeless management team. I can’t see how MM can rattle the tin without some kind of update on the two other phase II trials we have been waiting so long for. In fact it wasn’t long before the last CR, MM was proclaiming HIV trials were fully funded…. Compulsive liar.